Global Biosimilar Monoclonal Antibodies Market Growth 2025-2031

January 2025 | 113 pages | ID: GCB1AA42805EN
LP Information

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

The global Biosimilar Monoclonal Antibodies market size is predicted to grow from US$ 5955 million in 2025 to US$ 14960 million in 2031; it is expected to grow at a CAGR of 16.6% from 2025 to 2031.

Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies. Biosimilar Monoclonal Antibodies refer to the biologic medical product that are almost an identical copy of the original monoclonal antibodies but manufactured by a different company.

The biosimilar monoclonal antibodies market is primarily driven by the increasing demand for cost-effective biologic treatments. As patents for many original biologic drugs expire, biosimilars offer a more affordable alternative without compromising efficacy. This is particularly important in treating chronic diseases like cancer and autoimmune disorders, where long-term treatment costs can be prohibitive. The growing acceptance of biosimilars by healthcare providers and regulatory approvals in various regions further propels market growth. However, a key challenge facing the market is the complexity of manufacturing biosimilar monoclonal antibodies. Due to their structural intricacies, even minor variations in production processes can lead to differences in efficacy or safety compared to the original biologic. Additionally, patient and physician skepticism, driven by concerns over efficacy and potential side effects, can hinder widespread adoption, especially in markets where the original biologics are well-established. Global Biosimilar Monoclonal Antibodies key players include Celltrion, 3SBIO, Pfizer (Hospira), Novartis, etc. Global top four manufacturers hold a share nearly 85%. Europe is the largest market, with a share about 40%, followed by China, and United States, both have a share about 50 percent. In terms of product, Infliximab is the largest segment, with a share nearly 40%. And in terms of application, the largest application is Autoimmune Disease, followed by Oncology, etc.

LP Information, Inc. (LPI) ' newest research report, the “Biosimilar Monoclonal Antibodies Industry Forecast” looks at past sales and reviews total world Biosimilar Monoclonal Antibodies sales in 2024, providing a comprehensive analysis by region and market sector of projected Biosimilar Monoclonal Antibodies sales for 2025 through 2031. With Biosimilar Monoclonal Antibodies sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Biosimilar Monoclonal Antibodies industry.

This Insight Report provides a comprehensive analysis of the global Biosimilar Monoclonal Antibodies landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Biosimilar Monoclonal Antibodies portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Biosimilar Monoclonal Antibodies market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Biosimilar Monoclonal Antibodies and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Biosimilar Monoclonal Antibodies.

This report presents a comprehensive overview, market shares, and growth opportunities of Biosimilar Monoclonal Antibodies market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

• Infliximab
• Rituximab
• Trastuzumab
• Adalimumab
• Other

Segmentation by Application:

• Oncology
• Autoimmune Disease
• Other

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

• Celltrion
• Pfizer (Hospira)
• 3SBIO
• Novartis (Sandoz)
• Dr Reddy’s
• Celgen Biopharma
• Cadila Healthcare
• Hisun Pharma
• Torrent Pharmaceuticals
• Fresenius Kabi
• Coherus Solutions
• Biogen
• Amgen
• Biocon Biologics
• Organon

Key Questions Addressed in this Report

What is the 10-year outlook for the global Biosimilar Monoclonal Antibodies market?

What factors are driving Biosimilar Monoclonal Antibodies market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Biosimilar Monoclonal Antibodies market opportunities vary by end market size?

How does Biosimilar Monoclonal Antibodies break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Biosimilar Monoclonal Antibodies Annual Sales 2020-2031
  2.1.2 World Current & Future Analysis for Biosimilar Monoclonal Antibodies by Geographic Region, 2020, 2024 & 2031
  2.1.3 World Current & Future Analysis for Biosimilar Monoclonal Antibodies by Country/Region, 2020, 2024 & 2031
2.2 Biosimilar Monoclonal Antibodies Segment by Type
  2.2.1 Infliximab
  2.2.2 Rituximab
  2.2.3 Trastuzumab
  2.2.4 Adalimumab
  2.2.5 Other
2.3 Biosimilar Monoclonal Antibodies Sales by Type
  2.3.1 Global Biosimilar Monoclonal Antibodies Sales Market Share by Type (2020-2025)
  2.3.2 Global Biosimilar Monoclonal Antibodies Revenue and Market Share by Type (2020-2025)
  2.3.3 Global Biosimilar Monoclonal Antibodies Sale Price by Type (2020-2025)
2.4 Biosimilar Monoclonal Antibodies Segment by Application
  2.4.1 Oncology
  2.4.2 Autoimmune Disease
  2.4.3 Other
2.5 Biosimilar Monoclonal Antibodies Sales by Application
  2.5.1 Global Biosimilar Monoclonal Antibodies Sale Market Share by Application (2020-2025)
  2.5.2 Global Biosimilar Monoclonal Antibodies Revenue and Market Share by Application (2020-2025)
  2.5.3 Global Biosimilar Monoclonal Antibodies Sale Price by Application (2020-2025)

3 GLOBAL BY COMPANY

3.1 Global Biosimilar Monoclonal Antibodies Breakdown Data by Company
  3.1.1 Global Biosimilar Monoclonal Antibodies Annual Sales by Company (2020-2025)
  3.1.2 Global Biosimilar Monoclonal Antibodies Sales Market Share by Company (2020-2025)
3.2 Global Biosimilar Monoclonal Antibodies Annual Revenue by Company (2020-2025)
  3.2.1 Global Biosimilar Monoclonal Antibodies Revenue by Company (2020-2025)
  3.2.2 Global Biosimilar Monoclonal Antibodies Revenue Market Share by Company (2020-2025)
3.3 Global Biosimilar Monoclonal Antibodies Sale Price by Company
3.4 Key Manufacturers Biosimilar Monoclonal Antibodies Producing Area Distribution, Sales Area, Product Type
  3.4.1 Key Manufacturers Biosimilar Monoclonal Antibodies Product Location Distribution
  3.4.2 Players Biosimilar Monoclonal Antibodies Products Offered
3.5 Market Concentration Rate Analysis
  3.5.1 Competition Landscape Analysis
  3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR BIOSIMILAR MONOCLONAL ANTIBODIES BY GEOGRAPHIC REGION

4.1 World Historic Biosimilar Monoclonal Antibodies Market Size by Geographic Region (2020-2025)
  4.1.1 Global Biosimilar Monoclonal Antibodies Annual Sales by Geographic Region (2020-2025)
  4.1.2 Global Biosimilar Monoclonal Antibodies Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Biosimilar Monoclonal Antibodies Market Size by Country/Region (2020-2025)
  4.2.1 Global Biosimilar Monoclonal Antibodies Annual Sales by Country/Region (2020-2025)
  4.2.2 Global Biosimilar Monoclonal Antibodies Annual Revenue by Country/Region (2020-2025)
4.3 Americas Biosimilar Monoclonal Antibodies Sales Growth
4.4 APAC Biosimilar Monoclonal Antibodies Sales Growth
4.5 Europe Biosimilar Monoclonal Antibodies Sales Growth
4.6 Middle East & Africa Biosimilar Monoclonal Antibodies Sales Growth

5 AMERICAS

5.1 Americas Biosimilar Monoclonal Antibodies Sales by Country
  5.1.1 Americas Biosimilar Monoclonal Antibodies Sales by Country (2020-2025)
  5.1.2 Americas Biosimilar Monoclonal Antibodies Revenue by Country (2020-2025)
5.2 Americas Biosimilar Monoclonal Antibodies Sales by Type (2020-2025)
5.3 Americas Biosimilar Monoclonal Antibodies Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Biosimilar Monoclonal Antibodies Sales by Region
  6.1.1 APAC Biosimilar Monoclonal Antibodies Sales by Region (2020-2025)
  6.1.2 APAC Biosimilar Monoclonal Antibodies Revenue by Region (2020-2025)
6.2 APAC Biosimilar Monoclonal Antibodies Sales by Type (2020-2025)
6.3 APAC Biosimilar Monoclonal Antibodies Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan

7 EUROPE

7.1 Europe Biosimilar Monoclonal Antibodies by Country
  7.1.1 Europe Biosimilar Monoclonal Antibodies Sales by Country (2020-2025)
  7.1.2 Europe Biosimilar Monoclonal Antibodies Revenue by Country (2020-2025)
7.2 Europe Biosimilar Monoclonal Antibodies Sales by Type (2020-2025)
7.3 Europe Biosimilar Monoclonal Antibodies Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Biosimilar Monoclonal Antibodies by Country
  8.1.1 Middle East & Africa Biosimilar Monoclonal Antibodies Sales by Country (2020-2025)
  8.1.2 Middle East & Africa Biosimilar Monoclonal Antibodies Revenue by Country (2020-2025)
8.2 Middle East & Africa Biosimilar Monoclonal Antibodies Sales by Type (2020-2025)
8.3 Middle East & Africa Biosimilar Monoclonal Antibodies Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Biosimilar Monoclonal Antibodies
10.3 Manufacturing Process Analysis of Biosimilar Monoclonal Antibodies
10.4 Industry Chain Structure of Biosimilar Monoclonal Antibodies

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel
  11.1.1 Direct Channels
  11.1.2 Indirect Channels
11.2 Biosimilar Monoclonal Antibodies Distributors
11.3 Biosimilar Monoclonal Antibodies Customer

12 WORLD FORECAST REVIEW FOR BIOSIMILAR MONOCLONAL ANTIBODIES BY GEOGRAPHIC REGION

12.1 Global Biosimilar Monoclonal Antibodies Market Size Forecast by Region
  12.1.1 Global Biosimilar Monoclonal Antibodies Forecast by Region (2026-2031)
  12.1.2 Global Biosimilar Monoclonal Antibodies Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Biosimilar Monoclonal Antibodies Forecast by Type (2026-2031)
12.7 Global Biosimilar Monoclonal Antibodies Forecast by Application (2026-2031)

13 KEY PLAYERS ANALYSIS

13.1 Celltrion
  13.1.1 Celltrion Company Information
  13.1.2 Celltrion Biosimilar Monoclonal Antibodies Product Portfolios and Specifications
  13.1.3 Celltrion Biosimilar Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2020-2025)
  13.1.4 Celltrion Main Business Overview
  13.1.5 Celltrion Latest Developments
13.2 Pfizer (Hospira)
  13.2.1 Pfizer (Hospira) Company Information
  13.2.2 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Product Portfolios and Specifications
  13.2.3 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2020-2025)
  13.2.4 Pfizer (Hospira) Main Business Overview
  13.2.5 Pfizer (Hospira) Latest Developments
13.3 3SBIO
  13.3.1 3SBIO Company Information
  13.3.2 3SBIO Biosimilar Monoclonal Antibodies Product Portfolios and Specifications
  13.3.3 3SBIO Biosimilar Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2020-2025)
  13.3.4 3SBIO Main Business Overview
  13.3.5 3SBIO Latest Developments
13.4 Novartis (Sandoz)
  13.4.1 Novartis (Sandoz) Company Information
  13.4.2 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Product Portfolios and Specifications
  13.4.3 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2020-2025)
  13.4.4 Novartis (Sandoz) Main Business Overview
  13.4.5 Novartis (Sandoz) Latest Developments
13.5 Dr Reddy’s
  13.5.1 Dr Reddy’s Company Information
  13.5.2 Dr Reddy’s Biosimilar Monoclonal Antibodies Product Portfolios and Specifications
  13.5.3 Dr Reddy’s Biosimilar Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2020-2025)
  13.5.4 Dr Reddy’s Main Business Overview
  13.5.5 Dr Reddy’s Latest Developments
13.6 Celgen Biopharma
  13.6.1 Celgen Biopharma Company Information
  13.6.2 Celgen Biopharma Biosimilar Monoclonal Antibodies Product Portfolios and Specifications
  13.6.3 Celgen Biopharma Biosimilar Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2020-2025)
  13.6.4 Celgen Biopharma Main Business Overview
  13.6.5 Celgen Biopharma Latest Developments
13.7 Cadila Healthcare
  13.7.1 Cadila Healthcare Company Information
  13.7.2 Cadila Healthcare Biosimilar Monoclonal Antibodies Product Portfolios and Specifications
  13.7.3 Cadila Healthcare Biosimilar Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2020-2025)
  13.7.4 Cadila Healthcare Main Business Overview
  13.7.5 Cadila Healthcare Latest Developments
13.8 Hisun Pharma
  13.8.1 Hisun Pharma Company Information
  13.8.2 Hisun Pharma Biosimilar Monoclonal Antibodies Product Portfolios and Specifications
  13.8.3 Hisun Pharma Biosimilar Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2020-2025)
  13.8.4 Hisun Pharma Main Business Overview
  13.8.5 Hisun Pharma Latest Developments
13.9 Torrent Pharmaceuticals
  13.9.1 Torrent Pharmaceuticals Company Information
  13.9.2 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Product Portfolios and Specifications
  13.9.3 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2020-2025)
  13.9.4 Torrent Pharmaceuticals Main Business Overview
  13.9.5 Torrent Pharmaceuticals Latest Developments
13.10 Fresenius Kabi
  13.10.1 Fresenius Kabi Company Information
  13.10.2 Fresenius Kabi Biosimilar Monoclonal Antibodies Product Portfolios and Specifications
  13.10.3 Fresenius Kabi Biosimilar Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2020-2025)
  13.10.4 Fresenius Kabi Main Business Overview
  13.10.5 Fresenius Kabi Latest Developments
13.11 Coherus Solutions
  13.11.1 Coherus Solutions Company Information
  13.11.2 Coherus Solutions Biosimilar Monoclonal Antibodies Product Portfolios and Specifications
  13.11.3 Coherus Solutions Biosimilar Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2020-2025)
  13.11.4 Coherus Solutions Main Business Overview
  13.11.5 Coherus Solutions Latest Developments
13.12 Biogen
  13.12.1 Biogen Company Information
  13.12.2 Biogen Biosimilar Monoclonal Antibodies Product Portfolios and Specifications
  13.12.3 Biogen Biosimilar Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2020-2025)
  13.12.4 Biogen Main Business Overview
  13.12.5 Biogen Latest Developments
13.13 Amgen
  13.13.1 Amgen Company Information
  13.13.2 Amgen Biosimilar Monoclonal Antibodies Product Portfolios and Specifications
  13.13.3 Amgen Biosimilar Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2020-2025)
  13.13.4 Amgen Main Business Overview
  13.13.5 Amgen Latest Developments
13.14 Biocon Biologics
  13.14.1 Biocon Biologics Company Information
  13.14.2 Biocon Biologics Biosimilar Monoclonal Antibodies Product Portfolios and Specifications
  13.14.3 Biocon Biologics Biosimilar Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2020-2025)
  13.14.4 Biocon Biologics Main Business Overview
  13.14.5 Biocon Biologics Latest Developments
13.15 Organon
  13.15.1 Organon Company Information
  13.15.2 Organon Biosimilar Monoclonal Antibodies Product Portfolios and Specifications
  13.15.3 Organon Biosimilar Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2020-2025)
  13.15.4 Organon Main Business Overview
  13.15.5 Organon Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION


LIST OFTABLES

Table 1. Biosimilar Monoclonal Antibodies Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Biosimilar Monoclonal Antibodies Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Infliximab
Table 4. Major Players of Rituximab
Table 5. Major Players ofTrastuzumab
Table 6. Major Players of Adalimumab
Table 7. Major Players of Other
Table 8. Global Biosimilar Monoclonal Antibodies Sales byType (2020-2025) & (K Units)
Table 9. Global Biosimilar Monoclonal Antibodies Sales Market Share byType (2020-2025)
Table 10. Global Biosimilar Monoclonal Antibodies Revenue byType (2020-2025) & ($ million)
Table 11. Global Biosimilar Monoclonal Antibodies Revenue Market Share byType (2020-2025)
Table 12. Global Biosimilar Monoclonal Antibodies Sale Price byType (2020-2025) & (US$/Unit)
Table 13. Global Biosimilar Monoclonal Antibodies Sale by Application (2020-2025) & (K Units)
Table 14. Global Biosimilar Monoclonal Antibodies Sale Market Share by Application (2020-2025)
Table 15. Global Biosimilar Monoclonal Antibodies Revenue by Application (2020-2025) & ($ million)
Table 16. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Application (2020-2025)
Table 17. Global Biosimilar Monoclonal Antibodies Sale Price by Application (2020-2025) & (US$/Unit)
Table 18. Global Biosimilar Monoclonal Antibodies Sales by Company (2020-2025) & (K Units)
Table 19. Global Biosimilar Monoclonal Antibodies Sales Market Share by Company (2020-2025)
Table 20. Global Biosimilar Monoclonal Antibodies Revenue by Company (2020-2025) & ($ millions)
Table 21. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Company (2020-2025)
Table 22. Global Biosimilar Monoclonal Antibodies Sale Price by Company (2020-2025) & (US$/Unit)
Table 23. Key Manufacturers Biosimilar Monoclonal Antibodies Producing Area Distribution and Sales Area
Table 24. Players Biosimilar Monoclonal Antibodies Products Offered
Table 25. Biosimilar Monoclonal Antibodies Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 26. New Products and Potential Entrants
Table 27. Market M&A Activity & Strategy
Table 28. Global Biosimilar Monoclonal Antibodies Sales by Geographic Region (2020-2025) & (K Units)
Table 29. Global Biosimilar Monoclonal Antibodies Sales Market Share Geographic Region (2020-2025)
Table 30. Global Biosimilar Monoclonal Antibodies Revenue by Geographic Region (2020-2025) & ($ millions)
Table 31. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Geographic Region (2020-2025)
Table 32. Global Biosimilar Monoclonal Antibodies Sales by Country/Region (2020-2025) & (K Units)
Table 33. Global Biosimilar Monoclonal Antibodies Sales Market Share by Country/Region (2020-2025)
Table 34. Global Biosimilar Monoclonal Antibodies Revenue by Country/Region (2020-2025) & ($ millions)
Table 35. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Country/Region (2020-2025)
Table 36. Americas Biosimilar Monoclonal Antibodies Sales by Country (2020-2025) & (K Units)
Table 37. Americas Biosimilar Monoclonal Antibodies Sales Market Share by Country (2020-2025)
Table 38. Americas Biosimilar Monoclonal Antibodies Revenue by Country (2020-2025) & ($ millions)
Table 39. Americas Biosimilar Monoclonal Antibodies Sales byType (2020-2025) & (K Units)
Table 40. Americas Biosimilar Monoclonal Antibodies Sales by Application (2020-2025) & (K Units)
Table 41. APAC Biosimilar Monoclonal Antibodies Sales by Region (2020-2025) & (K Units)
Table 42. APAC Biosimilar Monoclonal Antibodies Sales Market Share by Region (2020-2025)
Table 43. APAC Biosimilar Monoclonal Antibodies Revenue by Region (2020-2025) & ($ millions)
Table 44. APAC Biosimilar Monoclonal Antibodies Sales byType (2020-2025) & (K Units)
Table 45. APAC Biosimilar Monoclonal Antibodies Sales by Application (2020-2025) & (K Units)
Table 46. Europe Biosimilar Monoclonal Antibodies Sales by Country (2020-2025) & (K Units)
Table 47. Europe Biosimilar Monoclonal Antibodies Revenue by Country (2020-2025) & ($ millions)
Table 48. Europe Biosimilar Monoclonal Antibodies Sales byType (2020-2025) & (K Units)
Table 49. Europe Biosimilar Monoclonal Antibodies Sales by Application (2020-2025) & (K Units)
Table 50. Middle East & Africa Biosimilar Monoclonal Antibodies Sales by Country (2020-2025) & (K Units)
Table 51. Middle East & Africa Biosimilar Monoclonal Antibodies Revenue Market Share by Country (2020-2025)
Table 52. Middle East & Africa Biosimilar Monoclonal Antibodies Sales byType (2020-2025) & (K Units)
Table 53. Middle East & Africa Biosimilar Monoclonal Antibodies Sales by Application (2020-2025) & (K Units)
Table 54. Key Market Drivers & Growth Opportunities of Biosimilar Monoclonal Antibodies
Table 55. Key Market Challenges & Risks of Biosimilar Monoclonal Antibodies
Table 56. Key IndustryTrends of Biosimilar Monoclonal Antibodies
Table 57. Biosimilar Monoclonal Antibodies Raw Material
Table 58. Key Suppliers of Raw Materials
Table 59. Biosimilar Monoclonal Antibodies Distributors List
Table 60. Biosimilar Monoclonal Antibodies Customer List
Table 61. Global Biosimilar Monoclonal Antibodies SalesForecast by Region (2026-2031) & (K Units)
Table 62. Global Biosimilar Monoclonal Antibodies RevenueForecast by Region (2026-2031) & ($ millions)
Table 63. Americas Biosimilar Monoclonal Antibodies SalesForecast by Country (2026-2031) & (K Units)
Table 64. Americas Biosimilar Monoclonal Antibodies Annual RevenueForecast by Country (2026-2031) & ($ millions)
Table 65. APAC Biosimilar Monoclonal Antibodies SalesForecast by Region (2026-2031) & (K Units)
Table 66. APAC Biosimilar Monoclonal Antibodies Annual RevenueForecast by Region (2026-2031) & ($ millions)
Table 67. Europe Biosimilar Monoclonal Antibodies SalesForecast by Country (2026-2031) & (K Units)
Table 68. Europe Biosimilar Monoclonal Antibodies RevenueForecast by Country (2026-2031) & ($ millions)
Table 69. Middle East & Africa Biosimilar Monoclonal Antibodies SalesForecast by Country (2026-2031) & (K Units)
Table 70. Middle East & Africa Biosimilar Monoclonal Antibodies RevenueForecast by Country (2026-2031) & ($ millions)
Table 71. Global Biosimilar Monoclonal Antibodies SalesForecast byType (2026-2031) & (K Units)
Table 72. Global Biosimilar Monoclonal Antibodies RevenueForecast byType (2026-2031) & ($ millions)
Table 73. Global Biosimilar Monoclonal Antibodies SalesForecast by Application (2026-2031) & (K Units)
Table 74. Global Biosimilar Monoclonal Antibodies RevenueForecast by Application (2026-2031) & ($ millions)
Table 75. Celltrion Basic Information, Biosimilar Monoclonal Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 76. Celltrion Biosimilar Monoclonal Antibodies Product Portfolios and Specifications
Table 77. Celltrion Biosimilar Monoclonal Antibodies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 78. Celltrion Main Business
Table 79. Celltrion Latest Developments
Table 80. Pfizer (Hospira) Basic Information, Biosimilar Monoclonal Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 81. Pfizer (Hospira) Biosimilar Monoclonal Antibodies Product Portfolios and Specifications
Table 82. Pfizer (Hospira) Biosimilar Monoclonal Antibodies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 83. Pfizer (Hospira) Main Business
Table 84. Pfizer (Hospira) Latest Developments
Table 85. 3SBIO Basic Information, Biosimilar Monoclonal Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 86. 3SBIO Biosimilar Monoclonal Antibodies Product Portfolios and Specifications
Table 87. 3SBIO Biosimilar Monoclonal Antibodies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 88. 3SBIO Main Business
Table 89. 3SBIO Latest Developments
Table 90. Novartis (Sandoz) Basic Information, Biosimilar Monoclonal Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 91. Novartis (Sandoz) Biosimilar Monoclonal Antibodies Product Portfolios and Specifications
Table 92. Novartis (Sandoz) Biosimilar Monoclonal Antibodies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 93. Novartis (Sandoz) Main Business
Table 94. Novartis (Sandoz) Latest Developments
Table 95. Dr Reddy’s Basic Information, Biosimilar Monoclonal Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 96. Dr Reddy’s Biosimilar Monoclonal Antibodies Product Portfolios and Specifications
Table 97. Dr Reddy’s Biosimilar Monoclonal Antibodies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 98. Dr Reddy’s Main Business
Table 99. Dr Reddy’s Latest Developments
Table 100. Celgen Biopharma Basic Information, Biosimilar Monoclonal Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 101. Celgen Biopharma Biosimilar Monoclonal Antibodies Product Portfolios and Specifications
Table 102. Celgen Biopharma Biosimilar Monoclonal Antibodies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 103. Celgen Biopharma Main Business
Table 104. Celgen Biopharma Latest Developments
Table 105. Cadila Healthcare Basic Information, Biosimilar Monoclonal Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 106. Cadila Healthcare Biosimilar Monoclonal Antibodies Product Portfolios and Specifications
Table 107. Cadila Healthcare Biosimilar Monoclonal Antibodies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 108. Cadila Healthcare Main Business
Table 109. Cadila Healthcare Latest Developments
Table 110. Hisun Pharma Basic Information, Biosimilar Monoclonal Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 111. Hisun Pharma Biosimilar Monoclonal Antibodies Product Portfolios and Specifications
Table 112. Hisun Pharma Biosimilar Monoclonal Antibodies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 113. Hisun Pharma Main Business
Table 114. Hisun Pharma Latest Developments
Table 115.Torrent Pharmaceuticals Basic Information, Biosimilar Monoclonal Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 116.Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Product Portfolios and Specifications
Table 117.Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 118.Torrent Pharmaceuticals Main Business
Table 119.Torrent Pharmaceuticals Latest Developments
Table 120.Fresenius Kabi Basic Information, Biosimilar Monoclonal Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 121.Fresenius Kabi Biosimilar Monoclonal Antibodies Product Portfolios and Specifications
Table 122.Fresenius Kabi Biosimilar Monoclonal Antibodies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 123.Fresenius Kabi Main Business
Table 124.Fresenius Kabi Latest Developments
Table 125. Coherus Solutions Basic Information, Biosimilar Monoclonal Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 126. Coherus Solutions Biosimilar Monoclonal Antibodies Product Portfolios and Specifications
Table 127. Coherus Solutions Biosimilar Monoclonal Antibodies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 128. Coherus Solutions Main Business
Table 129. Coherus Solutions Latest Developments
Table 130. Biogen Basic Information, Biosimilar Monoclonal Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 131. Biogen Biosimilar Monoclonal Antibodies Product Portfolios and Specifications
Table 132. Biogen Biosimilar Monoclonal Antibodies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 133. Biogen Main Business
Table 134. Biogen Latest Developments
Table 135. Amgen Basic Information, Biosimilar Monoclonal Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 136. Amgen Biosimilar Monoclonal Antibodies Product Portfolios and Specifications
Table 137. Amgen Biosimilar Monoclonal Antibodies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 138. Amgen Main Business
Table 139. Amgen Latest Developments
Table 140. Biocon Biologics Basic Information, Biosimilar Monoclonal Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 141. Biocon Biologics Biosimilar Monoclonal Antibodies Product Portfolios and Specifications
Table 142. Biocon Biologics Biosimilar Monoclonal Antibodies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 143. Biocon Biologics Main Business
Table 144. Biocon Biologics Latest Developments
Table 145. Organon Basic Information, Biosimilar Monoclonal Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 146. Organon Biosimilar Monoclonal Antibodies Product Portfolios and Specifications
Table 147. Organon Biosimilar Monoclonal Antibodies Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 148. Organon Main Business
Table 149. Organon Latest Developments



LIST OFFIGURES

Figure 1. Picture of Biosimilar Monoclonal Antibodies
Figure 2. Biosimilar Monoclonal Antibodies Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Biosimilar Monoclonal Antibodies Sales Growth Rate 2020-2031 (K Units)
Figure 7. Global Biosimilar Monoclonal Antibodies Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Biosimilar Monoclonal Antibodies Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Biosimilar Monoclonal Antibodies Sales Market Share by Country/Region (2024)
Figure 10. Biosimilar Monoclonal Antibodies Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Infliximab
Figure 12. Product Picture of Rituximab
Figure 13. Product Picture ofTrastuzumab
Figure 14. Product Picture of Adalimumab
Figure 15. Product Picture of Other
Figure 16. Global Biosimilar Monoclonal Antibodies Sales Market Share byType in 2025
Figure 17. Global Biosimilar Monoclonal Antibodies Revenue Market Share byType (2020-2025)
Figure 18. Biosimilar Monoclonal Antibodies Consumed in Oncology
Figure 19. Global Biosimilar Monoclonal Antibodies Market: Oncology (2020-2025) & (K Units)
Figure 20. Biosimilar Monoclonal Antibodies Consumed in Autoimmune Disease
Figure 21. Global Biosimilar Monoclonal Antibodies Market: Autoimmune Disease (2020-2025) & (K Units)
Figure 22. Biosimilar Monoclonal Antibodies Consumed in Other
Figure 23. Global Biosimilar Monoclonal Antibodies Market: Other (2020-2025) & (K Units)
Figure 24. Global Biosimilar Monoclonal Antibodies Sale Market Share by Application (2024)
Figure 25. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Application in 2025
Figure 26. Biosimilar Monoclonal Antibodies Sales by Company in 2025 (K Units)
Figure 27. Global Biosimilar Monoclonal Antibodies Sales Market Share by Company in 2025
Figure 28. Biosimilar Monoclonal Antibodies Revenue by Company in 2025 ($ millions)
Figure 29. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Company in 2025
Figure 30. Global Biosimilar Monoclonal Antibodies Sales Market Share by Geographic Region (2020-2025)
Figure 31. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Geographic Region in 2025
Figure 32. Americas Biosimilar Monoclonal Antibodies Sales 2020-2025 (K Units)
Figure 33. Americas Biosimilar Monoclonal Antibodies Revenue 2020-2025 ($ millions)
Figure 34. APAC Biosimilar Monoclonal Antibodies Sales 2020-2025 (K Units)
Figure 35. APAC Biosimilar Monoclonal Antibodies Revenue 2020-2025 ($ millions)
Figure 36. Europe Biosimilar Monoclonal Antibodies Sales 2020-2025 (K Units)
Figure 37. Europe Biosimilar Monoclonal Antibodies Revenue 2020-2025 ($ millions)
Figure 38. Middle East & Africa Biosimilar Monoclonal Antibodies Sales 2020-2025 (K Units)
Figure 39. Middle East & Africa Biosimilar Monoclonal Antibodies Revenue 2020-2025 ($ millions)
Figure 40. Americas Biosimilar Monoclonal Antibodies Sales Market Share by Country in 2025
Figure 41. Americas Biosimilar Monoclonal Antibodies Revenue Market Share by Country (2020-2025)
Figure 42. Americas Biosimilar Monoclonal Antibodies Sales Market Share byType (2020-2025)
Figure 43. Americas Biosimilar Monoclonal Antibodies Sales Market Share by Application (2020-2025)
Figure 44. United States Biosimilar Monoclonal Antibodies Revenue Growth 2020-2025 ($ millions)
Figure 45. Canada Biosimilar Monoclonal Antibodies Revenue Growth 2020-2025 ($ millions)
Figure 46. Mexico Biosimilar Monoclonal Antibodies Revenue Growth 2020-2025 ($ millions)
Figure 47. Brazil Biosimilar Monoclonal Antibodies Revenue Growth 2020-2025 ($ millions)
Figure 48. APAC Biosimilar Monoclonal Antibodies Sales Market Share by Region in 2025
Figure 49. APAC Biosimilar Monoclonal Antibodies Revenue Market Share by Region (2020-2025)
Figure 50. APAC Biosimilar Monoclonal Antibodies Sales Market Share byType (2020-2025)
Figure 51. APAC Biosimilar Monoclonal Antibodies Sales Market Share by Application (2020-2025)
Figure 52. China Biosimilar Monoclonal Antibodies Revenue Growth 2020-2025 ($ millions)
Figure 53. Japan Biosimilar Monoclonal Antibodies Revenue Growth 2020-2025 ($ millions)
Figure 54. South Korea Biosimilar Monoclonal Antibodies Revenue Growth 2020-2025 ($ millions)
Figure 55. Southeast Asia Biosimilar Monoclonal Antibodies Revenue Growth 2020-2025 ($ millions)
Figure 56. India Biosimilar Monoclonal Antibodies Revenue Growth 2020-2025 ($ millions)
Figure 57. Australia Biosimilar Monoclonal Antibodies Revenue Growth 2020-2025 ($ millions)
Figure 58. ChinaTaiwan Biosimilar Monoclonal Antibodies Revenue Growth 2020-2025 ($ millions)
Figure 59. Europe Biosimilar Monoclonal Antibodies Sales Market Share by Country in 2025
Figure 60. Europe Biosimilar Monoclonal Antibodies Revenue Market Share by Country (2020-2025)
Figure 61. Europe Biosimilar Monoclonal Antibodies Sales Market Share byType (2020-2025)
Figure 62. Europe Biosimilar Monoclonal Antibodies Sales Market Share by Application (2020-2025)
Figure 63. Germany Biosimilar Monoclonal Antibodies Revenue Growth 2020-2025 ($ millions)
Figure 64.France Biosimilar Monoclonal Antibodies Revenue Growth 2020-2025 ($ millions)
Figure 65. UK Biosimilar Monoclonal Antibodies Revenue Growth 2020-2025 ($ millions)
Figure 66. Italy Biosimilar Monoclonal Antibodies Revenue Growth 2020-2025 ($ millions)
Figure 67. Russia Biosimilar Monoclonal Antibodies Revenue Growth 2020-2025 ($ millions)
Figure 68. Middle East & Africa Biosimilar Monoclonal Antibodies Sales Market Share by Country (2020-2025)
Figure 69. Middle East & Africa Biosimilar Monoclonal Antibodies Sales Market Share byType (2020-2025)
Figure 70. Middle East & Africa Biosimilar Monoclonal Antibodies Sales Market Share by Application (2020-2025)
Figure 71. Egypt Biosimilar Monoclonal Antibodies Revenue Growth 2020-2025 ($ millions)
Figure 72. South Africa Biosimilar Monoclonal Antibodies Revenue Growth 2020-2025 ($ millions)
Figure 73. Israel Biosimilar Monoclonal Antibodies Revenue Growth 2020-2025 ($ millions)
Figure 74.Turkey Biosimilar Monoclonal Antibodies Revenue Growth 2020-2025 ($ millions)
Figure 75. GCC Countries Biosimilar Monoclonal Antibodies Revenue Growth 2020-2025 ($ millions)
Figure 76. Manufacturing Cost Structure Analysis of Biosimilar Monoclonal Antibodies in 2025
Figure 77. Manufacturing Process Analysis of Biosimilar Monoclonal Antibodies
Figure 78. Industry Chain Structure of Biosimilar Monoclonal Antibodies
Figure 79. Channels of Distribution
Figure 80. Global Biosimilar Monoclonal Antibodies Sales MarketForecast by Region (2026-2031)
Figure 81. Global Biosimilar Monoclonal Antibodies Revenue Market ShareForecast by Region (2026-2031)
Figure 82. Global Biosimilar Monoclonal Antibodies Sales Market ShareForecast byType (2026-2031)
Figure 83. Global Biosimilar Monoclonal Antibodies Revenue Market ShareForecast byType (2026-2031)
Figure 84. Global Biosimilar Monoclonal Antibodies Sales Market ShareForecast by Application (2026-2031)
Figure 85. Global Biosimilar Monoclonal Antibodies Revenue Market ShareForecast by Application (2026-2031)